News
Wed, 06 Nov 2024 05:17:00 -0500
Wed, 06 Nov 2024 05:17:00 -0500
|
PROFIT AND LOSS |
9M 2024 |
9M 2023 |
Growth as reported |
Growth at CER* |
|
USD million |
|
|
|
|
|
Net sales |
29,831 |
24,204 |
23% |
24% |
|
Operating profit |
13,348 |
11,027 |
21% |
22% |
|
|
|
|
|
|
|
Net profit |
10,602 |
8,978 |
18% |
N/A |
|
Diluted earnings per share (in USD) |
2.37 |
1.99 |
19% |
N/A |
|
* CER: Constant exchange rates (average 2023). |
|
|
|
|
|
** For convenience, Danish Kroner has been translated to USD in this release, using the average exchange rates of USD 1.0 = DKK 6.86262 and the period-end exchange rate of USD 1.0 = DKK 6.65952 |
||||
Lars Fruergaard Jørgensen, president and CEO: "We are pleased with the performance in the first nine months of 2024. The sales growth is driven by increasing demand for our GLP-1-based diabetes and obesity treatments, and we are serving more patients than ever before. Within R&D, we are very pleased about further read-outs across our semaglutide portfolio, including the SOUL trial in people living with diabetes and cardiovascular disease and the ESSENCE trial in people living with MASH."
On 6 November 2024 at 13.00 CET, corresponding to 07.00 am EST, an earnings call will be held. Investors will be able to listen in via a link on novonordisk.com, which can be found under ‘Investors’ (the contents of the company's website do not form a part of this Form 6-K).